BGM Group Enhances Healthcare Strategy with Acquisition
BGM Group Ltd. (Nasdaq: BGM) is set to make significant strides in the healthcare sector following its entry into a definitive transaction agreement to acquire Wonder Dragon Global Limited. This acquisition involves the exchange of 38,165,290 Class A ordinary shares at a price of $2 each, totaling a remarkable valuation of RMB550 million. This strategic move is anticipated to finalize by the conclusion of the second quarter of 2025.
Wonder Dragon's Exceptional Tea Inventory
The acquisition of Wonder Dragon is anchored by its impressive inventory of over 3,000 metric tons of premium Qingzhuan dark tea. This stock includes 1,670 metric tons of raw materials and 1,350 metric tons of finished tea products. Renowned for both their medicinal properties and collectible historical significance, these premium teas are poised to reinforce BGM Group’s research and development trajectories.
Strengthening Market Position in Healthcare
With this acquisition, BGM Group fortifies its foothold in the healthcare landscape. The company has consistently been a pioneer in blending cutting-edge AI technology, big data analytics, and biopharmaceutical innovations to revitalize traditional industries. After acquiring Wonder Dragon, the company intends to enhance the efficiency of tea production processes and improve the adaptability of its products, driving forward the development of active ingredients suitable for medicinal applications through its advanced AI-powered decision-making platform.
CEO's Vision for the Future
Mr. Xin Chen, the CEO of BGM Group, expressed his excitement about this acquisition, stating, "The resources available through Wonder Dragon’s Qingzhuan dark tea, when combined with our innovative biotechnology platform, will significantly bolster our ability to develop and distribute medicinal tea products. Our goal is to leverage technological advancements in introducing new health-centric tea options, such as ginseng and goji berry variants of Qingzhuan dark tea. This will effectively diversify our comprehensive product ecosystem that merges medicine, tea, and health."
About BGM Group Ltd
BGM Group Ltd is deeply entrenched in technology innovations across various domains, including AI applications, intelligent robotics, algorithmic computing, cloud computing, and biopharmaceutical advancements. The company employs big data mining and AI Agent technology to deliver comprehensive AI solutions and intelligent robotic services tailored for the insurance sector and beyond.
AI Solutions and Intelligent Robotics
Utilizing platforms like Du Xiao Bao and Bao Wang, BGM Group provides sophisticated services for insurance companies, brokers, and consumers. Their solutions span crucial operational areas, including sales and marketing, underwriting assessments, claims processing, and customer service. With robust data analytics capabilities, the group builds consumer profiles, forecasts insurance needs, and crafts highly personalized services for each customer.
Advancements in Biopharmaceuticals
In its biopharmaceutical division, BGM specializes in producing oxytetracycline API, crude heparin sodium, and licorice preparations. These products are extensively distributed across global markets, including animal husbandry and pharmaceutical retail sectors. Continuous integration of AI-assisted decision-making processes assures optimization across production and supply chains, enhances operational efficiency, and aids in predicting market trends.
Contact Information
BGM Group remains committed to engaging with investors and the media, offering a platform for inquiries about its innovations and initiatives. To connect, please reach out directly, ensuring prompt and attentive responses.
Frequently Asked Questions
1. What is the main purpose of BGM Group's latest acquisition?
The main goal is to enhance BGM Group's healthcare offerings through Wonder Dragon's premium tea products.
2. How does BGM Group intend to utilize Wonder Dragon's inventory?
BGM plans to optimize production efficiency and develop new medicinal tea products by leveraging advanced technology.
3. What technology does BGM Group employ in its services?
BGM utilizes AI technology and big data analytics to improve services in the insurance industry and beyond.
4. What products does BGM Group's biopharmaceutical division offer?
The division produces oxytetracycline API, crude heparin sodium, and licorice preparations for global markets.
5. How can investors and media reach BGM Group?
Interested parties can directly contact BGM Group for inquiries regarding their initiatives and progress.
